Sawyer & Company Inc Buys Shares of 57,691 Novo Nordisk A/S (NYSE:NVO)

Sawyer & Company Inc acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 57,691 shares of the company's stock, valued at approximately $4,963,000. Novo Nordisk A/S makes up about 1.8% of Sawyer & Company Inc's investment portfolio, making the stock its 15th biggest position.

A number of other large investors have also modified their holdings of NVO. Raymond James & Associates lifted its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company's stock worth $419,939,000 after buying an additional 36,223 shares in the last quarter. Natixis Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company's stock worth $366,125,000 after acquiring an additional 80,070 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its holdings in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company's stock valued at $162,266,000 after purchasing an additional 47,496 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $0.34 during trading on Thursday, hitting $83.26. 6,320,240 shares of the company traded hands, compared to its average volume of 8,102,344. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business's fifty day moving average is $98.82 and its 200-day moving average is $117.93. The stock has a market capitalization of $373.61 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.